Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia
Portfolio Pulse from
Tonix Pharmaceuticals presented data on TNX-102 SL, a potential new treatment for fibromyalgia, at an international congress. The drug showed significant pain reduction in Phase 3 trials and has a PDUFA date set for August 15, 2025.
March 04, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-102 SL demonstrated significant pain reduction in fibromyalgia patients in Phase 3 trials. The FDA decision is expected by August 2025, potentially making it the first new fibromyalgia drug in over 15 years.
The positive Phase 3 trial results for TNX-102 SL and the upcoming FDA decision are significant for Tonix Pharmaceuticals. Approval could lead to a new class of non-opioid analgesics for fibromyalgia, potentially boosting TNXP's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100